Clinical trial · no report yet · Phase 3
NCT05113251
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
- NCT05113251 ↗
- Active not recruiting
- AstraZeneca
- 224 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 84 | |
| YouTube | 81 | |
| Podcasts | 51 | |
| X videos | 8 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Breast Neoplasms; Breast Cancer; HER2-positive Early Breast Cancer
- Interventions
- Trastuzumab Deruxtecan; Paclitaxel; Trastuzumab; Pertuzumab; Doxorubicin; cyclophosphamide
- Arms
- Arm A · Experimental
- Arm B · Experimental
- Arm C · Active comparator
- Enrollment
- 927
- Primary outcomes
- Rate of Pathologic Complete Response (pCR).
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Oct 25, 2021
- Primary completion
- Mar 12, 2025
- Results posted
- Yes
- Registry record
- NCT05113251 · updated Aug 11, 2026